Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cook Will Appeal Ruling Against Guidant Paclitaxel Stent Distribution

This article was originally published in The Gray Sheet

Executive Summary

Guidant has vowed to "define an organizational construct" that "allows for the commercialization of paclitaxel-eluting stents," following a June 13 court ruling against its Cook distribution agreement for access to the drug

You may also be interested in...



Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%

Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months

Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%

Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months

Post-Paclitaxel: Will Boston Scientific Cut Guidant Royalty Deal?

Boston Scientific's reluctance to grant Medtronic a license in 2001 in its dispute over rapid-exchange delivery technology may set a precedent for the next stage of the Boston Scientific/Guidant fight over drug-eluting stents

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel